Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How?
Authors:
Open Access
- 12 August 2010
- journal article
- research article
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 33 (5) , 333-342
Abstract
Background: The cost and effectiveness patterns in the treatment of secondary hyperparathyroidism (SHPT) in dialysis patients in the Czech Republic are unknown. Methods: 52 dialysis patients from 17 centers were followed up in a multicenter prospective study of laboratory and clinical (hospitalization rate, clinical complaints questionnaire) responses to 12-month cinacalcet treatment. Treatment patterns and cost (including phosphate binders, vitamin D, and cinacalcet) were evaluated. Results: The mean s-Ca dropped significantly from 2.36 ± 0.24 to 2.21 ± 0.20 mmol/l, s-P from 2.45 ± 0.54 to 2.01 ± 0.53 mmol/l, Ca×P from 5.79 ± 1.25 to 4.42 ± 1.13 mmol2/l2, and iPTH dropped from 919.0 ± 465.6 to 372.1 ± 294.6 pg/ml. The mean cinacalcet dose reached 44.1 ± 23.0 mg/day after 12 months. Itching intensity decreased significantly. No change in hospitalization rate was observed. The direct cost of daily SHPT treatment rose significantly from EUR 8.77 ± 9.59 to 20.62 ± 9.22. Conclusions: Cinacalcet decreased elevated s-Ca, s-P, Ca×P, and iPTH, alleviated itching, and significantly raised the SHPT treatment cost. A minority of patients reached K/DOQI targets, especially due to poor phosphate control caused by insufficient phosphate binder treatment, cinacalcet underdosing, and advanced SHPT.Keywords
This publication has 20 references indexed in Scilit:
- Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidismNephrology Dialysis Transplantation, 2008
- Clinical Outcomes in Secondary Hyperparathyroidism and the Potential Role of CalcimimeticsClinical Kidney Journal, 2008
- Secondary Hyperparathyroidism Disease Stabilization Following Calcimimetic TherapyClinical Kidney Journal, 2008
- The Role of the Calcium-Sensing Receptor in the Pathophysiology of Secondary HyperparathyroidismClinical Kidney Journal, 2008
- The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOSClinical Kidney Journal, 2008
- Parathyroidectomy Versus Cinacalcet Hydrochloride–Based Medical Therapy in the Management of Hyperparathyroidism in ESRD: A Cost Utility AnalysisAmerican Journal of Kidney Diseases, 2007
- Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysisNephrology Dialysis Transplantation, 2007
- Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HClNephrology Dialysis Transplantation, 2005
- Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving HemodialysisNew England Journal of Medicine, 2004
- Calcimimetics with potent and selective activity on the parathyroid calcium receptorProceedings of the National Academy of Sciences, 1998